Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration

Journal of Pharmaceutical Sciences

Volumn 102, Issue 3, 2013, Pages 794-812

  Kwong Glover, Zephania W ^a   Gennaro, Lynn ^a   Yadav, Sandeep ^a   Demeule, Barthélemy ^a   Wong, Pin Yee ^a   Sreedhara, Alavattam ^a  

^a GENENTECH INC   (United States)

Author keywords

Admixture; Herceptin ; Intravenous administration; Parenteral; Perjeta ; Physical stability; RhuMAb 2C4; RhuMAb HER2

Indexed keywords

PERTUZUMAB; POLYOLEFIN; POLYVINYLCHLORIDE; TRASTUZUMAB;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOASSAY; BIOPHYSICS; CANCER INHIBITION; CAPILLARY ISOELECTRIC FOCUSING; CAPILLARY ZONE ELECTROPHORESIS; CELL PROLIFERATION; COLOR; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DILUTION; DRUG MIXTURE; DRUG POTENCY; DRUG STABILITY; DRUG STORAGE; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; ION EXCHANGE CHROMATOGRAPHY; PARTICULATE MATTER; PHYSICAL CHEMISTRY; STORAGE TEMPERATURE; TURBIDITY; ULTRACENTRIFUGATION; ULTRAVIOLET SPECTROSCOPY;

EID: 84878132756     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23403     Document Type: Article

References (62)

1. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. 2004. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96(10):739-749.
2. Nahta R, Hung MC, Esteva FJ. 2004. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64(7):2343-2346.
3. Boye J, Elter T, Engert A. 2003. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol (14):520-535.
4. Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA. 2006. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 24(24):3880-3886.
5. Stabile LP, Rothstein ME, Keohavong P, Lenzner D, Land SR, Gaither-Davis AL, Kim KJ, Kaminski N, JM S. 2010. Targeting of both the c-Met and EGFR pathways results in additive inhibition of lung tumorigenesis in transgenic mice. Cancers (Basel) 2(4):2153-2170.
6. Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, SS R. 2008. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: A multicenter phase 2 study. Cancer 113(9):2512-2517.
7. Galun E, Eren R, Safadi R, Ashour Y, Terrault N, Keeffe EB, Matot E, Mizrachi S, Terkieltaub D, Zohar M, Lubin I, Gopher J, Shouval D, Dagan S. 2002. Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties. Hepatology 35(4):673-679.
8. Lokich JJ, Zipoli TE, Moore C, Sonneborn H, Paul S, Greene R. 1986. Doxorubicin/vinblastine and doxorubicin/cyclophosphamide combination chemotherapy by continuous infusion. Cancer 58(5):1020-1023.
9. Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. 1996. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 18(2):246-255.
10. Williams DA. 1996. Drug stability and compatibility in oncology care. J Infus Chemother 6(4):195-202.
11. Kupie TC, Trusley C, Ben M, Trissel LA. 2008. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health Syst Pharm 65(18):1735-1759.
12. Menard C, Bourguignon C, Schlatter J, Vermerie N. 2003. Stability of cyclophosphamide and mesna admixtures in polyethylene infusion bags. Ann Pharmacother 37(12):1789-1792.
13. Zhang Y, Xu QA, Trissel LA, Gilbert DL, Martinez JF. 1997. Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions. Ann Pharmacother 31(12):1465-1470.
14. Bergquist PA, Manas D, Hunke WA, Reed RA. 2001. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health Syst Pharm 58(13):1218-1223.
15. Boyle DA, Goldspiel BR. 1998. A review of paclitaxel (Taxol) administration, stability, and compatibility issues. Clin J Oncol Nurs 2(4):141-145.
16. Sreedhara A, Glover ZK, Piros N, Xiao N, Patel A, Kabakoff B. 2012. Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions. J Pharm Sci 101(1):21-30.
17. Kumru OS, Liu J, Ji JA, Cheng W, Wang YJ, Wang T, Joshi SB, Middaugh CR, Volkin DB. 2012. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. J Pharm Sci 101(10):3636-3650.
18. Chang JY, Xiao NJ, Zhu M, Zhang J, Hoff E, Russell SJ, Katta V, Shire SJ. 2010. Leachables from saline-containing IV bags can alter therapeutic protein properties. Pharm Res 27(11):2402-2413.
19. Mahler HC, Friess W, Grauschopf U, Kiese S. 2009. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98(9):2909-2934.
20. Cleland JL, Powell MF, Shire SJ. 1993. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 10(4):307-377.
21. Manning M, Chou D, Murphy B, Payne RW, Katayama D. 2010. Stability of protein pharmaceuticals: An update. Pharm Res 27(4):544-575.
22. Fischer S, Hoernschemeyer J, Mahler HC. 2008. Glycation during storage and administration of monoclonal antibody formulations. Eur J Pharm Biopharm Sep 70(1):42-50.
23. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. 2009. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15(5):429-440.
24. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. 2004. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5(4):317-328.
25. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. 2005. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23(11):2534-2543.
26. Sheridan C. 2012. FDA approves pertuzumab. Nat Biotechnol 30(7):570-570.
27. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. 2012. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New Engl J Med 366(2):109-119.
28. Akscin J, Barr TR, Towle EL. 2007. Benchmarking practice operations: Results from a survey of office-based oncology practices. J Oncol Pract 3:9-12.
29. Perez EA, Lopez-Vega JM, Del Mastro L, Petit T, Pelizon C, Andersson M. 2012. A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2- positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET). ASCO AnnualMeeting. J Clin Oncol. 30 (suppl; abstr TPS653)
30. Kienle PC. 2007. Understanding beyond-use dating for compounded sterile preparation. Pharm Purch Prod 4(3):2-5.
31. Bardin C, Astier A, Vulto A, Sewell G, Vigneron J, Trittler R, Daouphars M, Paul M, Trojniak M, Pinguet F. 2011. Guidelines for the practical stability studies of anticancer drugs: A European consensus conference. Ann Pharm Fr 69(4):221-231.
32. Vigneron J. 2006. Stability studies of drugs used in oncology: The role of the hospital pharmacist. Eur J Hosp Pharm Sci 12:75-76.
33. Schuck P. 2000. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J 78(3):1606-1619.
34. Padlan EA. 1994. Anatomy of the antibody molecule. Mol Immunol 31(3):169-217.
35. Atomic Coordinate Files for Whole IgG1. Accessed, at: http://www.umass.edu/microbio/rasmol/padlan.htm. August 2011.
36. Eswar N, John B, Mirkovic N, Fiser A, Ilyin VA, Pieper U, Stuart AC, Marti-Renom MA, Madhusudhan MS, Yerkovich B, Sali A. 2003. Tools for comparative protein structure modeling and analysis. Nucleic Acids Res 31(13):3375-3380.
37. Berendsen HJC, Vanderspoel D, Vandrunen R. 1995. Gromacs-A message-passing parallel molecular-dynamics implementation. Comput Phys Commun 91(1-3):43-56.
38. Laskowski RA, Macarthur MW, Moss DS, Thornton JM. 1993. Procheck-A program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:283-291.
39. Hooft RWW, Sander C, Vriend G. 1997. Objectively judging the quality of a protein structure from a Ramachandran plot. Comput Appl Biosci 13(4):425-430.
40. Schodinger L. 2010. The PyMOL Molecular Graphics System, Version 1.2r1.
41. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. 2001. Electrostatics of nanosystems: Application to microtubules and the ribosome. Proc Natl Acad Sci U S A 98(18):10037-10041.
42. Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G, Baker NA. 2007. PDB2PQR: Expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res 35:W522-W525.
43. Dolinsky TJ, Nielsen JE, McCammon JA, Baker NA. 2004. PDB2PQR: An automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res 32:W665-W667.
44. Sorin EJ, Pande VS. 2005. Exploring the helix-coil transition via all-atom equilibrium ensemble simulations. Biophys J 88(4):2472-2493.
45. Li H, Robertson AD, Jensen JH. 2005. Very fast empirical prediction and rationalization of protein pK(a) values. Proteins 61(4):704-721.
46. Protein properties calculator, Scientific Vector Language (SVL) source code provided by Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, Quebec, Canada, H3A 2R7, 2011.
47. Demeule B, Messick S, Shire SJ, Liu J. 2010. Characterization of particles in protein solutions: Reaching the limits of current technologies. AAPS J 12(4):708-715.
48. Hunt G, Nashabeh W. 1999. Capillary electrophoresis sodium dodecyl sulfate nongel sieving analysis of a therapeutic recombinant monoclonal antibody: A biotechnology perspective. Anal Chem 71(13):2390-2397.
49. Liu J, Lester P, Builder S, Shire SJ. 1995. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34(33):10474-10482.
50. Sreedhara A, Demeule B, Liu J, Yadav S, Cromwell M, Shire SJ. 2012. Biophysical analysis in support of development of protein pharmaceuticals. In Biophysics for therapeutic protein development; Narhi LO, Ed. New York City, New York: Springer.
51. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. 2001. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B 752(2):233-245.
52. Yadav S, Shire SJ, Kalonia DS. 2012. Viscosity behavior of high-concentration monoclonal antibody solutions: Correlation with interaction parameter and electroviscous effects. J Pharm Sci 101(3):998-1011.
53. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. 2009. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 98(4):1201-1205.
54. Rosenberg AS, Verthelyi D, Cherney BW. 2012. Managing uncertainty: A perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. J Pharm Sci 101(10):3560-3567.
55. Narhi LO, Jiang Y, Cao S, Benedek K, Shnek D. 2009. A critical review of analytical methods for subvisible and visible particles. Curr Pharm Biotechnol 10(4):373-381.
56. Salas-Solano O, Tomlinson B, Du S, Parker M, Strahan A, Ma S. 2006. Optimization and validation of a quantitative capillary electrophoresis sodium dodecyl sulfate method for quality control and stability monitoring of monoclonal antibodies. Anal Chem 78(18):6583-6594.
57. Bonten EJ, Campos Y, Zaitsev V, Nourse A, Waddell B, Lewis W, Taylor G, d'Azzo A. 2009. Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization. J Biolog Chem 284(41):28430-28441.
58. Vlasak J, Ionescu R. 2008. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Curr Pharm Biotechnol 9(6):468-481.
59. Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar D, Nijem I, Allison DE, Wong PY, Kao YH, Quan C, Joshi A, Harris RJ, Motchnik P. 2010. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs 2(6):613-624.
60. Lyubarskaya Y, Houde D, Woodard J, Murphy D, Mhatre R. 2006. Analysis of recombinant monoclonal antibody isoforms by electrospray ionization mass spectrometry as a strategy for streamlining characterization of recombinant monoclonal antibody charge heterogeneity. Anal Biochem 348(1):24-39.
61. Zheng JY, Janis LJ. 2006. Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. Int J Pharm 308(1-2):46-51.
62. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. 2009. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69(24):9330-9336.